{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:31Z","timestamp":1791078871467,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1100,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1111\/j.1365-2133.2012.11156.x","type":"journal-article","created":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T16:00:04Z","timestamp":1346083204000},"page":"678-687","source":"Crossref","is-referenced-by-count":76,"title":["Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00"],"prefix":"10.1093","volume":"167","author":[{"given":"S.","family":"Whittaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Meulemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Knobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karrasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB1|cit1","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organisation for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB4|cit4","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: a validation of the revised ISCL\/EORTC proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsey","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides: a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long term follow-up","volume":"33","author":"Hermann","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 6","key":"10.1111\/j.1365-2133.2012.11156.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0190-9622(84)70030-2","article-title":"Photochemotherapy for cutaneous T cell lymphoma. A follow-up study","volume":"10","author":"Honigsmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.136.6.748","article-title":"Narrowband TL-01 phototherapy for patch-stage mycosis fungoides","volume":"136","author":"Clark","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB22|cit22","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2307\/2529759","article-title":"On the use of Pocock and Simon\u2019s method for balancing treatment numbers over prognostic factors in the controlled clinical trial","volume":"32","author":"Freedman","year":"1976","journal-title":"Biometrics"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/archderm.135.10.1204","article-title":"Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept","volume":"135","author":"Schmid","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB28|cit28","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"10","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"issue":"Suppl. 18s","key":"10.1111\/j.1365-2133.2012.11156.x-BIB32|cit32","article-title":"Prospective multicenter randomized clinical trial on the use of interferon alfa 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma stages I and II. ASCO Annual Meeting Proceedings, Part 1","volume":"24","author":"Stadler","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/j.1365-2133.2012.11156.x-BIB35|cit35","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides plaque stage","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2012.11156.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2012.11156.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:56:47Z","timestamp":1676365007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/3\/678\/6614069"}},"subtitle":["PUVA vs. PUVA and bexarotene for treatment of MF"],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11156.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717955151.793460793","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717955151.793461163","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717955151.793461600","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,27]]}}}